STOCK TITAN

PERRIGO Co plc (PRGO) SEC Filings

PRGO NYSE

Perrigo Company plc filings document a consumer health issuer organized under Irish law, with disclosures covering operating results, non-GAAP measures, segment reporting, capital structure, governance, and material corporate events. Recent 8-K filings report quarterly earnings from continuing operations, the company's transition to product-category segments, and the completed sale of its Dermacosmetics branded business.

The filing record also covers Perrigo's ordinary shares, senior notes, revolving credit facility, and term loan arrangements, including amendments to credit agreements. Proxy and annual meeting materials document board matters, shareholder voting results, executive compensation, and the shareholder-approved 2026 Long-Term Incentive Plan.

Rhea-AI Summary

Perrigo Co plc (PRGO) was named in an amended ownership report by Fuller & Thaler Asset Management, Inc., which reported beneficial ownership of 5,433,779 common shares, or 3.92% of the class. The asset manager reported sole voting power over 5,423,874 shares and sole dispositive power over 5,433,779 shares, with no shared voting or dispositive power.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
ownership
-
Rhea-AI Summary

Perrigo Company plc (PRGO) reported third-quarter net sales of $988.6 million, compared with $1,043.3 million a year earlier, and a net loss of $27.5 million versus net income of $7.5 million. For the nine months ended September 26, 2026, net sales were $2,980.6 million, compared with $3,143.5 million, and net loss was $351.6 million versus a net loss of $7.3 million.

Operating loss for the nine months was $325.8 million, including $335.9 million in impairment charges, compared with operating income of $164.9 million and impairment charges of $4.6 million in the prior-year period. Net cash from operating activities was $65.2 million, compared with $63.1 million.

Perrigo completed the Dermacosmetics Business sale on April 30, 2026, for total consideration of $362.9 million, net of cash delivered, and recorded a $129.5 million pretax gain. Consideration included €305.6 million ($358.5 million) upfront cash, $6.2 million for inventory, less $1.8 million of cash delivered; up to an additional €27.0 million is contingent on net-sales milestones, with €18.0 million remaining through 2027. Cash and cash equivalents were $436.6 million as of September 26, 2026, and total borrowings outstanding were $3,294.1 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
quarterly report
-
Rhea-AI Summary

Perrigo Company plc reported third-quarter 2026 results from continuing operations, with All In net sales of $988.6 million, down 5.2% year over year, and adjusted diluted EPS of $0.60, down 25.0%. Reported diluted EPS from continuing operations was $(0.10), compared with $0.09 a year earlier; consolidated net loss was $27.5 million. Core net sales were $908.1 million, down 1.7%, and Core adjusted EPS was $0.61, down 9.0%. All In adjusted operating margin was 13.1%, versus 16.6%.

After quarter-end, Perrigo announced an agreement to sell Infant Formula for total consideration of up to $175 million: $40 million in cash at closing and up to $135 million contingent on net-sales milestones through 2030. Perrigo expects a $275.0 million to $375.0 million impairment loss in the fourth quarter of 2026. Fiscal 2026 Core adjusted EPS outlook is $2.15 to $2.35, compared with prior guidance of $2.25 to $2.55. Third-quarter operating cash flow was $96 million; cash was $436.6 million and total debt was $3.3 billion as of September 26, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
current report
Rhea-AI Summary

Perrigo Company plc (PRGO) entered a definitive agreement for MeridianMade to acquire its Infant Formula business for total consideration of up to $175 million: $40 million in cash at closing and up to $135 million contingent on future performance milestones through 2030.

Closing is expected in the first half of 2027, subject to customary closing conditions and regulatory approvals. Until closing, Perrigo will continue to own and operate the business, while it and MeridianMade operate independently. Infant Formula will remain in All In results for the third quarter of 2026 and, beginning in the fourth quarter, will be included in discontinued operations. In the trailing four quarters ended June 27, 2026, the business generated net sales of $380 million and segment adjusted operating income of $8 million. Perrigo expects a non-cash impairment charge of $275 million to $375 million in the fourth quarter of 2026. It also expects the transaction to enhance its margin profile, materially reduce expected future capital expenditures and make reported results more closely reflect Core Perrigo.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
current report
-
Rhea-AI Summary

PERRIGO Co plc (PRGO) director Geoffrey M. Parker reported an automatic conversion of 1,263 Restricted Stock Units into the same number of ordinary shares on September 11, 2026. At a reported value of $13.66 per share, 607 shares were delivered or withheld to cover the exercise price or tax liability, with the balance retained as ordinary shares. Following these transactions, Parker is reported as holding ordinary shares indirectly through a revocable trust and a Roth IRA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
insider
-
Rhea-AI Summary

PERRIGO Co plc (PRGO) director Bradley A. Alford reported equity award and related share transactions dated September 11, 2026. He exercised 1,263 Restricted Stock Units, receiving the same number of ordinary shares at $13.66 per share, with each unit representing one ordinary share.

Of the shares received, 607 ordinary shares were delivered or withheld for payment of exercise price or tax liability. Alford also received a new grant of 2,059 Restricted Stock Units, each representing a contingent right to one ordinary share, scheduled to vest on September 11, 2027. No Rule 10b5-1 trading plan is reported for these transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
insider
Rhea-AI Summary

PERRIGO Co plc (PRGO) reported that executive vice president and chief business development officer David Ball exercised 7,701 Restricted Stock Units on September 9, 2026, converting them into 7,701 ordinary shares at $14.34 per share. As part of this event, 2,784 ordinary shares were delivered or withheld to pay the exercise price or related tax liability. No Restricted Stock Units remained from this award after the transaction, and no Rule 10b5-1 trading plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
insider
-
Rhea-AI Summary

PERRIGO Co plc (PRGO) received an amended Schedule 13G filing from T. Rowe Price Associates, Inc. reporting a significantly reduced position in its common stock. T. Rowe Price reports beneficial ownership of 231,010 shares, representing 0.1% of the class, with sole voting power over 225,136 shares and sole dispositive power over 231,010 shares.

T. Rowe Price states that it now holds 5% or less of Perrigo’s common stock and expressly denies being the beneficial owner of the reported securities beyond this technical reporting status.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
ownership
-
Rhea-AI Summary

T. Rowe Price Associates, Inc. reports beneficial ownership of 8,700,421 shares of Perrigo Company plc common stock, representing 6.3% of the class as of June 30, 2026. It has sole voting power over 8,666,232 shares and sole dispositive power over 8,700,421 shares, with no shared voting or dispositive power.

The firm states that this report should not be construed as an admission that it is the beneficial owner of these securities and expressly denies such beneficial ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
ownership
Form 10-Q
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.10%
Tags
quarterly report

FAQ

How many PERRIGO Co plc (PRGO) SEC filings are available on StockTitan?

StockTitan tracks 112 SEC filings for PERRIGO Co plc (PRGO), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for PERRIGO Co plc (PRGO)?

The most recent SEC filing for PERRIGO Co plc (PRGO) was filed on November 16, 2026.